ccc_R08

• CAT Number: I042365
• CAS Number: 2919019-72-8
• Molecular Formula: C22H19ClO6
• Molecular Weight: 414.84
• Purity: ≥95%
• Synonyms: 3-[2-[4-(8-chloro-4-oxochromen-2-yl)phenoxy]ethoxy]cyclobutane-1-carboxylic acid
• InChI: InChI=1S/C22H19ClO6/c23-18-3-1-2-17-19(24)12-20(29-21(17)18)13-4-6-15(7-5-13)27-8-9-28-16-10-14(11-16)22(25)26/h1-7,12,14,16H,8-11H2,(H,25,26)
• InChIKey: JFCQXBCQZCBQSI-UHFFFAOYSA-N
• SMILES: C1C(CC1OCCOC2=CC=C(C=C2)C3=CC(=O)C4=C(O3)C(=CC=C4)Cl)C(=O)O

ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection[1][2].
ccc_R08 (0.3, 1.0, 3.2, 10, 32 µM; 5 days) significantly reduces the level of cccDNA, protein-free RC-DNA, and double stranded linear DNA (DL-DNA) in HepDES19 cells[1].
ccc_R08 (0-100 µM) dose-dependently reduces the level of extracellular HBeAg from HepDES19 cells, with IC50 of ~0.1 µM[1].
ccc_R08 (20 mg/kg; p.o.; twice per day for 2 weeks) clears cccDNA from the liver of HBVcircle mice[1].
ccc_R08 (10, 15, 20, 30 mg/kg; p.o.; twice per day for 2 weeks) significantly decreases the serum level of pgRNA in a dose-dependent manner, and the reduction in pgRNA is quantitatively correlated with that in liver cccDNA at different doses[1].

Reference

[1]. Wang L, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3.
 [Content Brief]

[2]. Ligat G, et al. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatol Rep. 2020 Sep;19(3):235-244.
 [Content Brief]